Stay updated on Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new Revision: v3.4.2 has been added, and earlier entries including a government-funding notice and Revision: v3.4.1 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check21 days agoChange DetectedAdded an administrative notice about potential processing delays due to a lapse in government funding. Version updated from v3.4.0 to v3.4.1.SummaryDifference0.6%

- Check28 days agoChange DetectedGlossary visibility has been added, and the history view now uses green and red highlights to show additions and deletions, with an updated revision label (Revision: v3.4.0).SummaryDifference0.8%

- Check35 days agoChange DetectedA new revision entry v3.3.4 has been added to the history, and v3.3.3 has been removed. This keeps the historical record of the study's documentation up to date.SummaryDifference0.1%

- Check64 days agoChange DetectedA new 'Revision: v3.3.3' label appears on the page, while the 'HHS Vulnerability Disclosure' and the 'Revision: v3.3.2' entries are removed from the footer.SummaryDifference0.2%

- Check85 days agoChange DetectedThe latest record now shows Revision: v3.3.2 in the history, with v3.3.1 removed from the list. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Efficacy in Stage II-III NSCLC Clinical Trial page.